Press Release Archives - Page 19 of 22

Spectral Medical to Host Virtual Investor Day on December 4, 2020

TORONTO, Canada – November 27, 2020 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal...

Spectral Medical Announces that its wholly owned subsidiary Dialco Medical has received MDSAP certification

MDSAP is the highest quality and regulatory standard in the medical device industry TORONTO, Canada – November 24, 2020 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and...

Spectral Medical Announces Report on Clinical Implementation of SAMI Amid COVID-19 Published in the Journal of Blood Purification

Operating the SAMI viewed as both simple and safe by the nurses Successful remote deployment of SAMI with only 3 hours of virtual training Toronto, Ontario | November 11, 2020 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic...

Spectral and Dialco Sponsored Symposiums at the 38th Vicenza Course on AKI and CRRT

Toronto, Ontario | November 3, 2020 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) and its wholly-owned subsidiary Dialco Medical In. (“Dialco”), are pleased to announce the following sponsored symposiums at the virtual 38th Vicenza Course on AKI and...

Spectral to Present at H.C. Wainwright & Co. 22nd Annual Global Investment Conference

TORONTO, Canada – September 8, 2020 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), announced today that Dr. Paul Walker, Spectral’s Chief Executive Officer and Chris Seto, Spectral’s Chief Operating and Chief Financial Officer will be presenting...

U.S. FDA Grants 510(k) Clearance for Spectral’s DIMI

Immediately enables DIMI to be used within U.S. hospitals, clinics and skilled nursing facilities U.S. skilled nursing facilities market represents an estimated US$2 billion market annually TORONTO, Canada – August 31, 2020 – Spectral Medical Inc. (“Spectral” or the...

« Older Entries

Next Entries »

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.